<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1174</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">5</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2025</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">25</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.pdl1<br/><br/>

<div class='content chap10-para-head'><strong>Description</strong></div>
<div class='content chap10-para'>
<p>The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor (immunotherapy). PD-L1 is done for Non-small cell lung cancers (NSCLC).</p>

</div>

<div class='content chap10-para-head'><strong>Rationale</strong></div>
<div class='content chap10-para'>
<p>PD-L1 is recommended by treatment guidelines for lung cancer to determine if the patient may benefit from checkpoint inhibitor drugs (immunotherapy). It is a new data item for cases diagnosed 1/1/2025+.</p>

</div>



<div class='content chap10-para'><strong>Codes</strong></div>
<table>
        <tr class='code-row'><td class='code-nbr'>0.0</td><td class='code-desc'>No PD-L1 expression identified

Tumor Proportion Score (TPS) = 0%</td></tr>
        <tr class='code-row'><td class='code-nbr'>0.1-100.0</td><td class='code-desc'>0.1-100.0 PD-L1 expression

Tumor Proportion Score (TPS) = 0.1%-100.0%</td></tr>
        <tr class='code-row'><td class='code-nbr'>XXX.2</td><td class='code-desc'>PD-L1 expression absent AND

Tumor Proportion Score (TPS) stated as negative</td></tr>
        <tr class='code-row'><td class='code-nbr'>XXX.3</td><td class='code-desc'>PD-L1 expression present AND

Tumor Proportion Score (TPS) stated as low</td></tr>
        <tr class='code-row'><td class='code-nbr'>XXX.4</td><td class='code-desc'>PD-L1 expression present AND

Tumor Proportion Score (TPS) stated as high/positive</td></tr>
        <tr class='code-row'><td class='code-nbr'>XXX.7</td><td class='code-desc'>Test ordered, results not in chart</td></tr>
        <tr class='code-row'><td class='code-nbr'>XXX.8</td><td class='code-desc'>Not applicable: Information not collected for this case  
(If this item is required by your standard setter, use of code 8 will result in an edit error)</td></tr>
        <tr class='code-row'><td class='code-nbr'>XXX.9</td><td class='code-desc'>Not documented in medical record

No microscopic confirmation of tumor

PD-L1 cannot be determined

PD-L1 not assessed or unknown if assessed</td></tr>
        <tr class='code-row'><td class='code-nbr'>Blank</td><td class='code-desc'>NA - Diagnosis year is prior to 2025</td></tr>
</table>

<div class='content chap10-para'>
<p><strong>Note 1:</strong> This SSDI is effective for diagnosis years 2025+. </p>
<ul>
<li>For cases diagnosed 2018-2024, leave this SSDI blank</li>
</ul>
<p><strong>Note 2:</strong> Physician statement PD-L1 can be used to code this data item when no other information is available.</p>
<p><strong>Note 3:</strong> The absence or presence of PD-L1 expression determines if the tumor will respond to treatment with a targeted inhibitor. PDL-1 is done for Non-Small Cell lung cancers (NSCLC)</p>
<p><strong>Note 4:</strong> If neoadjuvant therapy is given, record the assay from tumor specimens prior to neoadjuvant therapy. </p>
<ul>
<li>If neoadjuvant therapy is given and there are no PD-L1 results from pre-treatment specimens, report the findings from post-treatment specimens</li>
</ul>

</div>
